CRISPR Therapeutics announced positive results from its Phase 1 clinical trial of CTX310, an in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3. At the highest dose cohort, patients achieved a mean reduction of 73% in circulating ANGPTL3 levels (maximum 89%), 55% in triglycerides (maximum 84%) and 49% in LDL cholesterol (maximum 87%) following a single intravenous infusion. Among participants with baseline triglycerides above 150 mg/dL, mean reductions reached 60% at therapeutic doses. These data mark the first demonstration that a single-course in vivo CRISPR treatment can durably lower key cardiovascular risk factors.

CTX310 was well tolerated across all dose levels, with no treatment-related serious adverse events reported and no Grade 3 or higher elevations in liver transaminases. Mild to moderate infusion-related reactions resolved without intervention. The absence of significant off-target effects in preliminary sequencing analyses further underscores the therapy’s safety, allowing CRISPR Therapeutics to advance CTX310 into planned Phase 1b trials focused on severe hypertriglyceridemia and mixed dyslipidemia populations.

Building on CTX310’s proof of concept, CRISPR Therapeutics is positioned to leverage its in vivo gene-editing platform across a broader cardiovascular portfolio, including next-generation candidates targeting PCSK9 and Lp(a). The company expects to initiate Phase 1b studies for CTX310 in mid-2026 and is exploring partnerships to scale manufacturing of CRISPR reagents. With a projected gene therapy market exceeding $36 billion by 2032, CTX310’s progress could serve as a catalyst for valuation gains and further investment into the company’s pipeline of precision-medicine assets.